

## Issue 3 - July 2021

12,69 billion	66	11,24 billion doses	92%	372	1.91 billion
Approved Vaccines Production	Vaccine Producing manufacturing sites	Total signed country deals	Transport Temperature +2 to +8 °C	Ongoing Clinical Trials vaccine candidates	Global population with at least 1 vaccine

Last updated on July 7th 2021

[Source link](#)

## Welcome
















We are pleased to present the third issue of the VACscene. This issue reveals some interesting insights on the Covid-19 vaccination landscape; we saw a higher vaccination rate for countries with local Covid-19 vaccine production. On the other hand, many developing countries are still lagging. This leads us to suspect that a combination of; 1) a lack of local / regional production capacity and 2) complex logistics, which possibly slow down the global vaccination process. We also see a general slowdown in global vaccination, which we hypothesize that a combination of; 1) prioritizing the second dose of most vaccines in an already vaccinated population and 2) the global production bottlenecks.

Europe has recently shown an increase in new infections, especially amongst the young population with the start of the summer holiday season. This could possibly lead to the fourth Covid-19 wave. We also observed that the efficacy of some Covid-19 vaccines are lower than expected.

We wish you stay informed with this new issue of VACscene.

Glyn Hughes & Frank Van Gelder

## Updates on the Covid-19 vaccine global production

Company name	Vaccine name	Production sites	Approved production	Signed deals	Approved countries	Vaccine type	Doses
 AstraZeneca	AZD1222	16	2,1 Billion	2.869.265.000	98	Non Replicating Viral Vector	2
 BIONTECH Pfizer	BNT162b2	8	3 Billion	3.104.570.075	84	mRNA	2
 moderna messenger therapeutics	mRNA - 1273	7	800 Million	1.340.000.000	46	mRNA	2
 SINOPHARM	BBIBP-CorV (Beijing)	3	1 Billion	148.038.000	41	Inactivated	2
 МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ	Sputnik V	6	390 Million	445.987.500	68	Non Replicating Viral Vector	2
 CanSinoBIO	Ad5-nCoV	4	500 Million	76.800.000	5	Non Replicating Viral Vector	2
 SERUM INSTITUTE OF INDIA PVT. LTD. Lysos Peenakalla Group	Covishield	1	200 Million	100.000.000	33	Non Replicating Viral Vector	2
 BHARAT BIOTECH	Covaxin	3	494,2 Milion	278.500.000	9	Inactivated	2
 janssen Johnson & Johnson	Ad26.COV2.S	8	1 Billion	851.100.000	41	Non Replicating Viral Vector	1
 sinovac	Coronavac	4	1,75 Billion	916.023.000	25	Inactivated	2
 ZFSW INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES	RBD-Dimer	1	1 Million	0	2	Protein Subunit	2
 BEKTOP	EpiVacCorona	1	5 Million	0	2	Protein Subunit	2
 KoviVac	KoviVac	1	3 Million	0	2	Inactivated	2
 RIBSP Research Institute for Biological Safety Problems	QazCovid-in	1	4 Million	0	2	Inactivated	2
 MINHAI 民海生物 MINHAI BIOTECHNOLOGY CO., LTD	SARS-CoV-2 Vaccine (Vero Cells)	1	1 Million	0	2	Inactivated	2
Shifa Pharmed industrial CO	Covid-19	1	1 Million	0	1	Inactivated	1

[Source link](#)

## Hot from the needle

### 1st International Pharma Logistics Masterclass

where business meets academics

September 7<sup>th</sup> until September 11<sup>th</sup>, 2021

Register now!

**Key Challenges**

**Innovative Forum**

**Academic & Industry Insights**

**Best practices & Network**

**University of Antwerp**  
City Campus,  
Antwerp Belgium

**For more information**  
[Click here](#)

**Presentations, debates & practical workshops for industry professionals and master students**

**Broadening industry experience together with supply chain experts**

**Sharing knowledge & insights in an international framework**

**Academic theory combined with strategic decision making and operational insights**

**METRANS**  
Transportation Consortium  
UK FCS&S

**PHARMA**  
WE CONNECT  
AERO

**University of Antwerp**

### WHO says 'global community' is 'failing' for lack of vaccine distribution

June 27th, 2021

[Read the full article](#)

### Covid booster: first 'variant vaccine' used in new Oxford trial

June 27th, 2021

[Read the full article](#)

### Covid-19 Africa: What is happening with vaccine supplies?

June 23th, 2021

[Read the full article](#)

### More than 4 million Brazilians have missed 2nd shot of vaccine

June 27th, 2021

[Read the full article](#)

### WHO expects to give emergency approval to 1-2 more COVID-19 vaccines in coming months

June 25th, 2021

[Read the full article](#)

## Vaccine clinical trial updates

Protein Subunit					
<b>FINLAY-FR-1</b>	<b>Recombinant Protein</b>	<b>CIGB-66</b>	<b>SCB-2019</b>	<b>UB-612</b>	<b>FINLAY-FR-2</b>
Instituto Finlay de Vacunas Cuba	Sonofi/GSK	Center for Genetic Engineering and Biotechnology (CIGB)	Clover	COVAXX	Instituto Finlay de Vacunas Cuba
4 trials in 1 country	4 trials in 2 countries	5 trials in 1 country	5 trials in 10 countries	4 trials in 1 country	3 trials in 1 country
Protein Subunit			Inactivated		
<b>NVX-CoV2373</b>	<b>Nanocovax</b>	<b>Recombinant (Sf9 cell)</b>	<b>COVOVAX</b>	<b>Inactivated (Vero Cells)</b>	<b>VLA2001</b>
Novavax	Nanogen	West China Hospital	Serum institute of India	Chinese Academy of Medical Sciences	ValNeva
5 trials in 6 countries	3 trials in 1 country	5 trials in 1 country	2 trials in 1 country	5 trials in 3 countries	3 trials in 1 country
RNA			DNA		
<b>CVnCoV</b>	<b>BNT162b1</b>	<b>mRNA</b>	<b>AG0302-COVID19</b>	<b>INO-4800</b>	<b>ZyCoV-C</b>
Curevac	Pfizer/BioNTech	Walvax	AnGes	Inovio	Zydus Cadila
5 trials in 4 countries	5 trials in 3 countries	4 trials in 1 country	4 trials in 1 country	6 trials in 3 countries	5 trials in 1 country
Non Replicating Viral Vector		VLP			
<b>GRAd-COV2</b>	<b>Plant-based VLP</b>				
ReiThera	Medicago				
5 trials in 12 countries	3 trials in 2 countries				

Last updated on June 28th 2021


[Source link](#)

## Global vaccine administration progress

### COVID-19 vaccine doses administered

Total number of vaccination doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses).

Our World  
in Data




Source: Official data collated by Our World in Data – Last updated <bound method GrapherBaseUpdater.time\_str of <cowidev.grapher.procs.vax.GrapherVaxUpdater object at 0x7f80b5f65250>> (London time)  
OurWorldInData.org/coronavirus • CC BY

Total: 1.91 billion  
Source link

### Share of the population fully vaccinated against COVID-19

Share of the total population that have received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.

Our World  
in Data




Source: Official data collated by Our World in Data – Last updated <bound method GrapherBaseUpdater.time\_str of <cowidev.grapher.procs.vax.GrapherVaxUpdater object at 0x7f80b5f65250>> (London time)  
OurWorldInData.org/coronavirus • CC BY

Source link

### Number of people fully vaccinated against COVID-19

Total number of people who received all doses prescribed by the vaccination protocol. This data is only available for countries which report the breakdown of doses administered by first and second doses.


Our World  
in Data



Source: Official data collated by Our World in Data – Last updated <bound method GrapherBaseUpdater.time\_str of <cowidev.grapher.procs.vax.GrapherVaxUpdater object at 0x7f80b5f65250>> (London time)  
OurWorldInData.org/coronavirus • CC BY

Source link

## Production forecast 2021



### China 2.613.000.000

Sinovac	1.013.000.000
Sinopharm	1.000.000.000
CanSinoBio	500.000.000
AstraZeneca	100.000.000

### US 2.260.000.000

BioTech Pfizer	1.000.000.000
Moderna	740.000.000
AstraZeneca	420.000.000
Bharat BioTech	100.000.000

### India 1.896.000.000

AstraZeneca	1.000.000.000
Bharat BioTech	570.000.000
SIOI	200.000.000
GNC	126.000.000

### Belgium 1.125.000.000

BioTech Pfizer	1.125.000.000
----------------	---------------

### Australia 50.000.000

AstraZeneca	50.000.000
-------------	------------

### Brazil 265.500.000

AstraZeneca	163.500.000
GNC	56.000.000
Sinovac	46.000.000

### Egypt 80.000.000

Sinovac	80.000.000
---------	------------

### France 108.000.000

Johnson&Johnson	108.000.000
-----------------	-------------

### Germany 796.000.000

BioTech Pfizer	750.000.000
GNC	36.000.000
AstraZeneca	10.000.000

### Indonesia 250.000.000

Sinovac	250.000.000
---------	-------------

### Italy 25.000.000

Johnson&Johnson	25.000.000
-----------------	------------

### Japan 30.000.000

AstraZeneca	30.000.000
-------------	------------

### Kazakhstan 5.640.000

GNC	5.640.000
-----	-----------

### Malaysia 15.000.000

Sinovac	12.000.000
CanSinoBio	3.000.000

### Mexico 285.000.000

AstraZeneca	250.000.000
CanSinoBio	35.000.000

### Netherlands 692.000.000

Johnson&Johnson	692.000.000
-----------------	-------------

### Pakistan 3.000.000

CanSinoBio	3.000.000
------------	-----------

### South Africa 150.000.000

Johnson&Johnson	150.000.000
-----------------	-------------

### South Korea 250.000.000

GNC	150.000.000
Moderna	100.000.000

### Spain 85.000.000

Moderna	60.000.000
Johnson&Johnson	25.000.000

### Switzerland 125.000.000

BioTech Pfizer	125.000.000
----------------	-------------

### Thailand 61.000.000

AstraZeneca	61.000.000
-------------	------------

### UAE 100.000.000

Sinopharm	100.000.000
-----------	-------------
















### UK 700.000.000

AstraZeneca	700.000.000
-------------	-------------

Source link



## Supply chain insights

Company name	Vaccine name	Product temperature	Transport temperature
 AstraZeneca	AZD1222	+2C° to +8C°	+2C° to +8C°
 BIONTECH Pfizer	BNT162b2	-70C°	+15C° to +25C°
 moderna™ <small>messenger therapeutics</small>	mRNA - 1273	-20C°	+2C° to +8C°
 SINOPHARM	BBIBP-CorV (Beijing)	+2C° to +8C°	+2C° to +8C°
 МИНИСТЕРСТВО ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ	Sputnik V	+2C° to +8C°	+2C° to +8C°
 CanSinoBIO	Ad5-nCoV	+2C° to +8C°	+2C° to +8C°
 SERUM INSTITUTE OF INDIA PVT. LTD. <small>CSIR-Poolawalla Group</small>	Covishield	+2C° to +8C°	+2C° to +8C°
 BHARAT BIOTECH	Covaxin	+2C° to +8C°	+2C° to +8C°
 janssen <small>PHARMACEUTICAL COMPANY OF JOHNSON &amp; JOHNSON</small>	Ad26.COV2.S	-20C°	+2C° to +8C°
 sinovac	Coronavac	+2C° to +8C°	+2C° to +8C°
 ZFSW INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES	RBD-Dimer	+2C° to +8C°	+2C° to +8C°
 BEKTOP	EpiVacCorona	+2C° to +8C°	+2C° to +8C°
 БАЛДИЖИК КОСМОНАВТИЧЕСКАЯ	KoviVac	+2C° to +8C°	+2C° to +8C°
 RIBSP Research Institute for Biological Safety Problems	QazCovid-in	+2C° to +8C°	+2C° to +8C°
 MINHAI 民海生物 MINHAI BIOTECHNOLOGY CO., LTD.	SARS-CoV-2 Vaccine (Vero Cells)	+2C° to +8C°	+2C° to +8C°
Shifa Pharmed industrial CO	Covid-19	+2C° to +8C°	+2C° to +8C°

[Source link](#)

### 4th of July Promotion

Register now through July 18th and get a free hotel night or dine on us.  
\*Eligibility depends on TIACA membership status



## Contact details

www.pharma.aero  
secgen@pharma.aero

www.tiaca.org  
secretariat@tiaca.org

www.4advice.eu  
info@4advice.eu

**Authors:**  
4Advice  
Pharma.Aero  
TIACA

This publication contains general information only and Pharma.Aero and TIACA are not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Pharma.Aero and TIACA shall not be responsible for any loss sustained by any person who relies on this publication.



Copyright © 2021 Pharma.Aero and TIACA. All rights reserved